TIA
REGN icon

Traphagen Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Traphagen Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$593K Sell
952
-33
-3% -$22.5K 0.04% 122
2026
Q1 		$761K Buy
985
+21
+2% +$16.1K 0.06% 96
2025
Q4 		$744K Buy
964
+53
+6% +$36K 0.06% 96
2025
Q3 		$512K Buy
911
+24
+3% +$13.6K 0.04% 118
2025
Q2 		$466K Buy
887
+117
+15% +$65.3K 0.04% 121
2025
Q1 		$488K Buy
770
+82
+12% +$56.4K 0.05% 113
2024
Q4 		$490K Buy
688
+233
+51% +$196K 0.05% 114
2024
Q3 		$478K Hold
455
– – 0.05% 109
2024
Q2 		$478K Sell
455
-290
-39% -$281K 0.05% 104
2024
Q1 		$718K Sell
745
-202
-21% -$192K 0.08% 83
2023
Q4 		$832K Sell
947
-202
-18% -$166K 0.1% 70
2023
Q3 		$946K Hold
1,149
– – 0.12% 52
2023
Q2 		$826K Sell
1,149
-2
-0.2% -$1.54K 0.11% 62
2023
Q1 		$946K Buy
1,151
+4
+0.3% +$3.02K 0.14% 54
2022
Q4 		$828K Hold
1,147
– – 0.13% 57
2022
Q3 		$790K Sell
1,147
-8
-0.7% -$5.04K 0.15% 51
2022
Q2 		$683K Buy
1,155
+6
+0.5% +$3.9K 0.12% 58
2022
Q1 		$802K Hold
1,149
– – 0.13% 50
2021
Q4 		$726K Hold
1,149
– – 0.12% 59
2021
Q3 		$695K Hold
1,149
– – 0.12% 54
2021
Q2 		$642K Hold
1,149
– – 0.11% 61
2021
Q1 		$544K Buy
1,149
+3
+0.3% +$1.46K 0.1% 71
2020
Q4 		$554K Buy
1,146
+5
+0.4% +$2.7K 0.1% 71
2020
Q3 		$639K Hold
1,141
– – 0.13% 58
2020
Q2 		$712K Hold
1,141
– – 0.16% 52
2020
Q1 		$557K Sell
1,141
-450
-28% -$186K 0.15% 56
2019
Q4 		$597K Hold
1,591
– – 0.14% 58
2019
Q3 		$441K Hold
1,591
– – 0.12% 69
2019
Q2 		$498K Hold
1,591
– – 0.13% 59
2019
Q1 		$653K Buy
+1,591
New +$655K 0.18% 46

Other funds holding REGN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
HCM
Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Traphagen Investment Advisors's REGN Position: Q2 2026 in Review

Traphagen Investment Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 3.4% in Q2 2026, selling an estimated $22.5K and leaving 952 shares worth $593K. The position accounts for 0.04% of the portfolio, ranked #122.

Traphagen Investment Advisors first reported a position in REGN in Q1 2019 and has held it in 30 quarters since. The position peaked at $946K in Q1 2023. 157 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Traphagen Investment Advisors held 952 shares of Regeneron Pharmaceuticals worth $593K as of Q2 2026.
  • Traphagen Investment Advisors sold 33 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $22.5K.
  • Regeneron Pharmaceuticals made up 0.04% of Traphagen Investment Advisors's portfolio in Q2 2026, its #122 holding.
  • Traphagen Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2019 and has held it in 30 quarters since.
  • Traphagen Investment Advisors's Regeneron Pharmaceuticals position peaked at $946K in Q1 2023.
  • 157 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Traphagen Investment Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.